Center for Medicare & Medicaid Services Releases Revised Guidance For Historic Medicare Drug Price Negotiation Program; By September 1, CMS Will Publish The List Of The First 10 Drugs Covered Under Part D Selected For Initial Price Applicability Year 2026
Portfolio Pulse from Benzinga Newsdesk
The Center for Medicare & Medicaid Services (CMS) has released revised guidance for its Medicare Drug Price Negotiation Program. By September 1, CMS will publish the list of the first 10 drugs covered under Part D selected for initial price applicability year 2026.
June 30, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
As a health service company, Cigna could be affected by changes in Medicare drug pricing.
The impact on Cigna's stock will depend on the specific drugs selected for price negotiation and how much of Cigna's revenue is derived from those drugs.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
As a health technology company, Clover Health may be indirectly affected by changes in Medicare drug pricing.
The impact on Clover Health's stock will depend on how changes in drug pricing affect the company's technology solutions and services.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 40
NEUTRAL IMPACT
As a managed care organization, Centene could be affected by changes in Medicare drug pricing.
The impact on Centene's stock will depend on the specific drugs selected for price negotiation and how much of Centene's revenue is derived from those drugs.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
As a pharmacy and healthcare company, CVS Health could be affected by changes in Medicare drug pricing.
The impact on CVS Health's stock will depend on the specific drugs selected for price negotiation and how much of CVS Health's revenue is derived from those drugs.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
NEUTRAL IMPACT
As an online marketplace for health insurance, eHealth could be indirectly affected by changes in Medicare drug pricing.
The impact on eHealth's stock will depend on how changes in drug pricing affect the health insurance plans available on its platform.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 40
NEUTRAL IMPACT
Elevate Credit, a fintech company, is not directly related to the healthcare sector and is unlikely to be affected by changes in Medicare drug pricing.
Elevate Credit operates in the fintech sector and is not directly involved in the healthcare or pharmaceutical industries.
CONFIDENCE 90
IMPORTANCE 10
RELEVANCE 10
NEUTRAL IMPACT
As a digital health insurance marketplace, GoHealth could be indirectly affected by changes in Medicare drug pricing.
The impact on GoHealth's stock will depend on how changes in drug pricing affect the health insurance plans available on its platform.
CONFIDENCE 70
IMPORTANCE 40
RELEVANCE 40
NEUTRAL IMPACT
As a health insurance company, Humana could be affected by changes in Medicare drug pricing.
The impact on Humana's stock will depend on the specific drugs selected for price negotiation and how much of Humana's revenue is derived from those drugs.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
As a diversified health care company, UnitedHealth Group could be affected by changes in Medicare drug pricing.
The impact on UnitedHealth Group's stock will depend on the specific drugs selected for price negotiation and how much of UnitedHealth Group's revenue is derived from those drugs.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60